Nerve Block, Pain, Postoperative, Robotic Surgical Procedures
Conditions
Keywords
Phase III, Randomized, Single blind, Single Center, Three arm, Non-inferiority
Brief summary
The study team aims to prospectively compare Placebo (local administration), ultrasound-guided transversus abdominis plane (UTAP) blocks, and laparoscopic-guided transversus abdominis plane (LTAP) blocks in patients undergoing robotic surgery of the prostate and kidney. The study team expects to be able to equally efficiently administer the blocks using direct visualization and ultrasound guidance. The study team expects that a negative result would obviate the need for longer operative time by eliminating the need for the separate ultrasound guided block while a positive result would demonstrate the increased utility of preoperative ultrasound blocks in managing postoperative pain.
Detailed description
Currently, ultrasound-guided transversus abdominis plane (UTAP) blocks (regional anesthetic blocks) are being employed for the care of urological surgery patients. Local and regional anesthesia is commonly used throughout surgical fields. However, ultrasound-guidance can be challenging, particularly in larger, obese patients. It is unknown how such techniques compare to laparoscopic-guided blockade, with respect to time to perform, learning curve, and postoperative analgesia. The transversus abdominis plane lies deep within the abdominal wall, potentially allowing for greater ease of access from a laparoscopic approach from within than the ultrasound guided percutaneous approach. Prior randomized studies have been completed comparing UTAP and Placebo. In 2012 Hosgood et al. compared UTAP and placebo (UTAP w/ saline) in 46 live-donor laparoscopic nephrectomy patients (24 UTAP vs. 22 placebo). Pain control (measured using the 0-10 VAS scale) was greater on post-operative day (POD) 1 in patients receiving UTAP than in controls, 19 (15) vs. 37 (20) (presented as mean (SD)), respectively. A similar randomized study in 2014 compared UTAP and placebo (UTAP w/saline) in 21 hand assisted laparoscopic nephrectomy patients (10 UTAP vs. 11 placebo). The study was initially powered for 50 patients but with decreased accrual secondary to a surgeon taking a leave of absence during the study period. Pain scores were recorded using the 0-10 VAS score. Postoperatively at 24 hours (median (IQR)) UTAP patients demonstrated decreased postoperative pain than placebo patients (1 (0-2) vs. 4 (2-6)) on the VAS score, respectively. A larger study, done in 2016, with 80 randomized patients undergoing retroperitoneal laparoscopic urologic surgery compared UTAP (40) and saline UTAP (40). Pain scores were assessed using the 0-100 VAS score scale. On POD1, UTAP group had lower pain scores (mean (SD)) of 8.4 (5.9) vs. placebo 28.3 (12.2). The most recent study, done in 2018, examined 100 randomized patients undergoing robotic-assisted laparoscopic prostatectomies. Fifty patients were given UTAP blocks while the others received no block. A Numerical Rating Scale (assumed to range from 0-10 as not otherwise specified) was used to assess pain. Patients receiving the block at 24 hours had better pain control (mean (SD)) (1.8 (0.82) vs. 3.57 (0.64)). While all of these studies point to potential efficacy of UTAP, no data has been published to date comparing laparoscopic administration of the TAP block (LTAP) to ultrasound guided administration. While these regional anesthetic blocks carry a theoretical risk of hematoma or damage to surrounding structures, none of the above studies report any complications with the injections. The study team aims to prospectively compare Placebo (local administration), UTAP, and LTAP blocks in patients undergoing robotic surgery of the prostate and kidney. The study team expects to be able to equally efficiently administer the blocks using direct visualization and ultrasound guidance. The study team expects that a negative result would obviate the need for longer operative time by eliminating the need for the separate ultrasound guided block while a positive result would demonstrate the increased utility of preoperative ultrasound blocks in managing postoperative pain.
Interventions
Direct injection of 0.25% bupivacaine into surgical wounds
bilateral TAP using ultrasound guidance in prostatectomies
bilateral TAP using laparoscopic guidance in prostatectomies
Sponsors
Study design
Masking description
A randomization service called Sealedenvelope.com available at https://www.sealedenvelope.com/simple-randomiser/v1/ will be used for allocation concealment to ensure that retrieval of the treatment group assignment is only revealed to appropriate team members on a real time basis after each new patient has been screened and consented. This service allows for allocation concealment that would not be possible if the entire randomization list was made available to team members at the beginning of the study. The security and integrity of the codes used by Sealedenvelope.com follows the Food and Drug Administration (FDA) standards for electronic records and follows the International Conference on Harmonisation Good Clinical Practice (ICH GCP) guidelines. Participants will be blinded to group allocation throughout the study. Due to the nature of the intervention, it is not possible to blind the investigator to group allocation.
Intervention model description
This is a single-center, single-blinded, (stratified) randomized placebo-controlled three-arm non-inferiority trial with 2:2:1 allocation ratio. People who meet eligibility requirements and provide informed consent will be randomly allocated to 3 groups to receive either UTAP, LTAP or Placebo with a 2:2:1 allocation ratio. The allocation sequence will be stratified by type of surgery (prostatectomy or partial nephrectomy) using stratified block randomization with randomly varying block sizes. Random permuted blocks sizes within stratification groups will be used to minimize the chance of selection bias. Investigators will be blinded to the size of each block with only the study statistician responsible for generating the randomization list knowing this information.
Eligibility
Inclusion criteria
* Age 18 years or older * Undergoing Robotic Assisted Laparoscopic Partial Nephrectomy or Robotic Assisted Laparoscopic Prostatectomy * Ability to understand and the willingness to sign a written informed consent.
Exclusion criteria
* Prior Partial Nephrectomy or Subtotal Prostatectomy Surgery (organ specific) * Conversion to open surgery * History of chronic pain * History of opiate or alcohol dependence * Allergies to local anesthetic * Retroperitoneal surgery * Single Port Surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual Analog Scale (VAS) | 24 hours post operatively | Visual analog scale (VAS) is a pain rating scale, with full scale from 0 to 10, higher score indicating more pain |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intraoperative Narcotic Use | up to 420 minutes | Intraoperative Narcotic Use in morphine equivalents |
| Intraoperative Ketoralac Use | up to 420 minutes | Intraoperative Ketoralac Use |
| Postoperative Narcotic Use | 24 hours post operatively | Postoperative Narcotic Use in morphine equivalents |
| Total Analgesic Medications | 24 hours post operatively | The 24-hour cumulative postoperative opioid analgesic requirement was calculated using standard tables to morphine equivalents. |
| Intraoperative Time and Block Time | up to 420 minutes | Intraoperative time taken to complete surgical blocks and operative |
| Number of Days to Return of Bowel Function | 2 weeks | Number of days to the return of bowel function |
| The Length of Hospital Stay | 2 weeks | Length of hospital stay from time of surgical completion to time of discharge. |
| VAS in Obese Patients | 24 hours post operatively | 24 hour postoperative pain scores recorded using the visual analog scale (VAS) in obese patients. Visual analog scale (VAS) is a pain rating scale, with full scale from 0 to 10, higher score indicating more pain. Comparison in patients with BMI \>30 and BMI\<30 |
| Number of Procedure Related Complications | 2 weeks | Procedure related complications and adverse events including bleeding or injection of anesthetic intravascular was determined according to Common Terminology Criteria for Adverse Events (CTCAE v 4.0). |
| The Amount of Ondansetron Use | 2 weeks | Use of antiemetic medications during the postoperative course |
Countries
United States
Participant flow
Recruitment details
196 patients were eligible for the study and initially randomized. A total of 143 prostatectomy patients were deemed appropriate candidates for the trial and randomized and 114 participants were then enrolled. A total of 53 partial nephrectomy patients were deemed appropriate candidates for the trial. 34 participants were randomized and then enrolled.
Participants by arm
| Arm | Count |
|---|---|
| Robotic -Guided Transversus Abdominus Plane (RTAP) Block 30mL of 0.25% bupivacaine injected bilaterally in the TAP plane using a RTAP through the assistant port with a laparoscopic needle driver guidance in prostatectomies. 40ml 0.25% bupivacaine unilateral will be administered in nephrectomy patients (weight based dosage permitting).
Bupivacain: Direct injection of 0.25% bupivacaine into surgical wounds
Laparoscopic-guided transversus abdominus plane block: bilateral TAP using laparoscopic guidance in prostatectomies | 56 |
| Ultrasound-guided Transversus Abdominus Plane (UTAP) Block 30mL of 0.25% bupivacaine administered to bilateral TAP using ultrasound guidance in prostatectomies. 40ml 0.25% aliquot bupivacaine unilateral administered in nephrectomy patients (weight based dosage permitting).
Bupivacain: Direct injection of 0.25% bupivacaine into surgical wounds
Ultrasound-guided transversus abdominus plane block: bilateral TAP using ultrasound guidance in prostatectomies | 64 |
| Placebo/Local Anesthesia Up to 60ml of 0.25% bupivacaine was injected directly into each of the port sites and specimen extraction site at the conclusion of the procedure prior to skin closure. | 28 |
| Total | 148 |
Baseline characteristics
| Characteristic | Robotic -Guided Transversus Abdominus Plane (RTAP) Block | Ultrasound-guided Transversus Abdominus Plane (UTAP) Block | Placebo/Local Anesthesia | Total |
|---|---|---|---|---|
| Age, Continuous | 62.1 years STANDARD_DEVIATION 9.5 | 63.0 years STANDARD_DEVIATION 10.6 | 63.7 years STANDARD_DEVIATION 6.6 | 62.8 years STANDARD_DEVIATION 9.5 |
| Body Mass Index (BMI) | 27.0 Kg/m^2 STANDARD_DEVIATION 4.14 | 28.6 Kg/m^2 STANDARD_DEVIATION 4.9 | 26.6 Kg/m^2 STANDARD_DEVIATION 4.25 | 27.5 Kg/m^2 STANDARD_DEVIATION 4.6 |
| Race and Ethnicity Not Collected | — | — | — | 0 Participants |
| Sex: Female, Male Female | 4 Participants | 4 Participants | 1 Participants | 9 Participants |
| Sex: Female, Male Male | 52 Participants | 60 Participants | 27 Participants | 139 Participants |
| Surgical Procedure Robotic Partial Nephrectomy (RPN) | 13 Participants | 13 Participants | 8 Participants | 34 Participants |
| Surgical Procedure Robotic Prostatectomy (RP) | 43 Participants | 51 Participants | 20 Participants | 114 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 28 | 0 / 64 | 0 / 56 |
| other Total, other adverse events | 0 / 28 | 0 / 64 | 0 / 56 |
| serious Total, serious adverse events | 0 / 28 | 0 / 64 | 0 / 56 |
Outcome results
Visual Analog Scale (VAS)
Visual analog scale (VAS) is a pain rating scale, with full scale from 0 to 10, higher score indicating more pain
Time frame: 24 hours post operatively
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo/Local Anesthesia | Visual Analog Scale (VAS) | 1.29 score on a scale | Standard Deviation 1.98 |
| Ultrasound-guided Transversus Abdominus Plane (UTAP) Block | Visual Analog Scale (VAS) | 3.16 score on a scale | Standard Deviation 3.1 |
| Robotic -Guided Transversus Abdominus Plane (RTAP) Block | Visual Analog Scale (VAS) | 2.89 score on a scale | Standard Deviation 2.69 |
Intraoperative Ketoralac Use
Intraoperative Ketoralac Use
Time frame: up to 420 minutes
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo/Local Anesthesia | Intraoperative Ketoralac Use | 0 mg |
| Ultrasound-guided Transversus Abdominus Plane (UTAP) Block | Intraoperative Ketoralac Use | 0 mg |
| Robotic -Guided Transversus Abdominus Plane (RTAP) Block | Intraoperative Ketoralac Use | 15 mg |
Intraoperative Narcotic Use
Intraoperative Narcotic Use in morphine equivalents
Time frame: up to 420 minutes
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo/Local Anesthesia | Intraoperative Narcotic Use | 27.0 morphine equivalents | Standard Deviation 12.6 |
| Ultrasound-guided Transversus Abdominus Plane (UTAP) Block | Intraoperative Narcotic Use | 24.1 morphine equivalents | Standard Deviation 12.64 |
| Robotic -Guided Transversus Abdominus Plane (RTAP) Block | Intraoperative Narcotic Use | 25.5 morphine equivalents | Standard Deviation 15.2 |
Intraoperative Time and Block Time
Intraoperative time taken to complete surgical blocks and operative
Time frame: up to 420 minutes
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Placebo/Local Anesthesia | Intraoperative Time and Block Time | Time Taken to Perform Block | 2.5 minutes |
| Placebo/Local Anesthesia | Intraoperative Time and Block Time | Total OR Time | 211.5 minutes |
| Ultrasound-guided Transversus Abdominus Plane (UTAP) Block | Intraoperative Time and Block Time | Time Taken to Perform Block | 6.0 minutes |
| Ultrasound-guided Transversus Abdominus Plane (UTAP) Block | Intraoperative Time and Block Time | Total OR Time | 224.5 minutes |
| Robotic -Guided Transversus Abdominus Plane (RTAP) Block | Intraoperative Time and Block Time | Time Taken to Perform Block | 2.5 minutes |
| Robotic -Guided Transversus Abdominus Plane (RTAP) Block | Intraoperative Time and Block Time | Total OR Time | 221 minutes |
Number of Days to Return of Bowel Function
Number of days to the return of bowel function
Time frame: 2 weeks
Population: Data not collected.
Number of Procedure Related Complications
Procedure related complications and adverse events including bleeding or injection of anesthetic intravascular was determined according to Common Terminology Criteria for Adverse Events (CTCAE v 4.0).
Time frame: 2 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo/Local Anesthesia | Number of Procedure Related Complications | 0 events |
| Ultrasound-guided Transversus Abdominus Plane (UTAP) Block | Number of Procedure Related Complications | 0 events |
| Robotic -Guided Transversus Abdominus Plane (RTAP) Block | Number of Procedure Related Complications | 0 events |
Postoperative Narcotic Use
Postoperative Narcotic Use in morphine equivalents
Time frame: 24 hours post operatively
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo/Local Anesthesia | Postoperative Narcotic Use | 14.13 morphine equivalents |
| Ultrasound-guided Transversus Abdominus Plane (UTAP) Block | Postoperative Narcotic Use | 19.50 morphine equivalents |
| Robotic -Guided Transversus Abdominus Plane (RTAP) Block | Postoperative Narcotic Use | 17 morphine equivalents |
The Amount of Ondansetron Use
Use of antiemetic medications during the postoperative course
Time frame: 2 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo/Local Anesthesia | The Amount of Ondansetron Use | 0.05 mg | Standard Deviation 0.19 |
| Ultrasound-guided Transversus Abdominus Plane (UTAP) Block | The Amount of Ondansetron Use | 0.31 mg | Standard Deviation 1.3 |
| Robotic -Guided Transversus Abdominus Plane (RTAP) Block | The Amount of Ondansetron Use | 0.29 mg | Standard Deviation 1.29 |
The Length of Hospital Stay
Length of hospital stay from time of surgical completion to time of discharge.
Time frame: 2 weeks
Population: Data not collected.
Total Analgesic Medications
The 24-hour cumulative postoperative opioid analgesic requirement was calculated using standard tables to morphine equivalents.
Time frame: 24 hours post operatively
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Placebo/Local Anesthesia | Total Analgesic Medications | Acetaminophen | 1650 mg morphine equivalents |
| Placebo/Local Anesthesia | Total Analgesic Medications | Ketorlac | 0 mg morphine equivalents |
| Placebo/Local Anesthesia | Total Analgesic Medications | Ondansetron | 0 mg morphine equivalents |
| Ultrasound-guided Transversus Abdominus Plane (UTAP) Block | Total Analgesic Medications | Acetaminophen | 1650 mg morphine equivalents |
| Ultrasound-guided Transversus Abdominus Plane (UTAP) Block | Total Analgesic Medications | Ketorlac | 30 mg morphine equivalents |
| Ultrasound-guided Transversus Abdominus Plane (UTAP) Block | Total Analgesic Medications | Ondansetron | 0 mg morphine equivalents |
| Robotic -Guided Transversus Abdominus Plane (RTAP) Block | Total Analgesic Medications | Ketorlac | 0 mg morphine equivalents |
| Robotic -Guided Transversus Abdominus Plane (RTAP) Block | Total Analgesic Medications | Ondansetron | 0 mg morphine equivalents |
| Robotic -Guided Transversus Abdominus Plane (RTAP) Block | Total Analgesic Medications | Acetaminophen | 1325 mg morphine equivalents |
VAS in Obese Patients
24 hour postoperative pain scores recorded using the visual analog scale (VAS) in obese patients. Visual analog scale (VAS) is a pain rating scale, with full scale from 0 to 10, higher score indicating more pain. Comparison in patients with BMI \>30 and BMI\<30
Time frame: 24 hours post operatively
Population: participants divided by BMI \>30 and BMI \<30
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo/Local Anesthesia | VAS in Obese Patients | BMI >30 | 1.29 score on a scale | Standard Deviation 2.21 |
| Placebo/Local Anesthesia | VAS in Obese Patients | BMI <30 | 1.29 score on a scale | Standard Deviation 1.95 |
| Ultrasound-guided Transversus Abdominus Plane (UTAP) Block | VAS in Obese Patients | BMI >30 | 4.09 score on a scale | Standard Deviation 2.94 |
| Ultrasound-guided Transversus Abdominus Plane (UTAP) Block | VAS in Obese Patients | BMI <30 | 2.67 score on a scale | Standard Deviation 3.11 |
| Robotic -Guided Transversus Abdominus Plane (RTAP) Block | VAS in Obese Patients | BMI >30 | 2.33 score on a scale | Standard Deviation 2.24 |
| Robotic -Guided Transversus Abdominus Plane (RTAP) Block | VAS in Obese Patients | BMI <30 | 3.00 score on a scale | Standard Deviation 2.75 |